1 results match your criteria: "Respiratory Center Asahikawa Medical University 2-1-1-1 Midorigaoka Higashi Asahikawa Japan.[Affiliation]"
A 70-year-old woman with lung adenocarcinoma, harbouring anaplastic lymphoma kinase gene rearrangement, was treated with crizotinib as third-line chemotherapy. After 2 months, crizotinib was discontinued because of the development of crizotinib-induced interstitial lung disease (ILD). Steroid treatment was then introduced and tapered off.
View Article and Find Full Text PDF